Exchange: NASDAQ·Updated 07:55 PM EDT
News
all
press releases
Why Liquidia Stock Was Diving This Week
Key PointsThe shares had risen by 155% year-to-date prior to earnings...
Nasdaq News: Markets
More News
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
Zacks
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Zacks
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.
Zacks
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
Zacks
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
Zacks
Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat
Net product sales for the second quarter surged to $170.4 million from $6.5 million last year, due to higher Yutrepia sales volumes.
Stocktwits
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
Zacks
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates
Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +5.71% and +3.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +15.70% and +148.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.